Premature Birth — Duodenal Feeds in Very Low Birth Weight Infants
Citation(s)
Blondheim O, Abbasi S, Fox WW, Bhutani VK Effect of enteral gavage feeding rate on pulmonary functions of very low birth weight infants. J Pediatr. 1993 May;122(5 Pt 1):751-5. doi: 10.1016/s0022-3476(06)80021-1.
Caillie MV, Powell GK Nasoduodenal versus nasogastric feeding in the very low birthweight infant. Pediatrics. 1975 Dec;56(6):1065-72.
Drew JH, Johnston R, Finocchiaro C, Taylor PS, Goldberg HJ A comparison of nasojejunal witn nasogastric feedings in low-birth-weight infants. Aust Paediatr J. 1979 Jun;15(2):98-100. doi: 10.1111/j.1440-1754.1979.tb01198.x. No abstract available.
Farhath S, Aghai ZH, Nakhla T, Saslow J, He Z, Soundar S, Mehta DI Pepsin, a reliable marker of gastric aspiration, is frequently detected in tracheal aspirates from premature ventilated neonates: relationship with feeding and methylxanthine therapy. J Pediatr Gastroenterol Nutr. 2006 Sep;43(3):336-41. doi: 10.1097/01.mpg.0000232015.56155.03.
Fenton TR, Nasser R, Eliasziw M, Kim JH, Bilan D, Sauve R Validating the weight gain of preterm infants between the reference growth curve of the fetus and the term infant. BMC Pediatr. 2013 Jun 11;13:92. doi: 10.1186/1471-2431-13-92.
Garland JS, Alex CP, Johnston N, Yan JC, Werlin SL Association between tracheal pepsin, a reliable marker of gastric aspiration, and head of bed elevation among ventilated neonates. J Neonatal Perinatal Med. 2014 Jan 1;7(3):185-92. doi: 10.3233/NPM-14814020.
Hsu CW, Sun SF, Lin SL, Kang SP, Chu KA, Lin CH, Huang HH Duodenal versus gastric feeding in medical intensive care unit patients: a prospective, randomized, clinical study. Crit Care Med. 2009 Jun;37(6):1866-72. doi: 10.1097/CCM.0b013e31819ffcda.
Jensen EA, Munson DA, Zhang H, Blinman TA, Kirpalani H Anti-gastroesophageal reflux surgery in infants with severe bronchopulmonary dysplasia. Pediatr Pulmonol. 2015 Jun;50(6):584-7. doi: 10.1002/ppul.23052. Epub 2014 Apr 21.
Jobe AH, Bancalari E Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9. doi: 10.1164/ajrccm.163.7.2011060. No abstract available.
Jolley SG, Halpern CT, Sterling CE, Feldman BH The relationship of respiratory complications from gastroesophageal reflux to prematurity in infants. J Pediatr Surg. 1990 Jul;25(7):755-7. doi: 10.1016/s0022-3468(05)80012-0.
Laing IA, Lang MA, Callaghan O, Hume R Nasogastric compared with nasoduodenal feeding in low birthweight infants. Arch Dis Child. 1986 Feb;61(2):138-41. doi: 10.1136/adc.61.2.138.
Malcolm WF, Smith PB, Mears S, Goldberg RN, Cotten CM Transpyloric tube feeding in very low birthweight infants with suspected gastroesophageal reflux: impact on apnea and bradycardia. J Perinatol. 2009 May;29(5):372-5. doi: 10.1038/jp.2008.234. Epub 2009 Feb 26.
McGuire W, McEwan P Transpyloric versus gastric tube feeding for preterm infants. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003487. doi: 10.1002/14651858.CD003487.pub2.
Misra S, Macwan K, Albert V Transpyloric feeding in gastroesophageal-reflux-associated apnea in premature infants. Acta Paediatr. 2007 Oct;96(10):1426-9. doi: 10.1111/j.1651-2227.2007.00442.x. Epub 2007 Sep 10.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.